Trials / Conditions / Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8

Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8

11 registered clinical trials studyying Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers NCT05296005	Ohio State University Comprehensive Cancer Center	Phase 1
Recruiting	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno NCT05041153	M.D. Anderson Cancer Center	EARLY_Phase 1
Active Not Recruiting	Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of NCT04929392	City of Hope Medical Center	Phase 2
Active Not Recruiting	Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance NCT04391049	NRG Oncology	Phase 1
Recruiting	Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv NCT04660760	Academic and Community Cancer Research United	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso NCT04460937	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer NCT04522336	M.D. Anderson Cancer Center	Phase 1
Completed	Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esopha NCT04097028	Roswell Park Cancer Institute	Phase 2
Completed	Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574	National Cancer Institute (NCI)	—
Active Not Recruiting	Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal NCT03784326	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer NCT03776487	M.D. Anderson Cancer Center	Phase 2